Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4902725 | 0.89 | FNTA (0.46) | MEN1KMT2ANPC1RAB9ASIGMAR1 | |
| SCHEMBL6324160 | 0.79 | ALDH1A1 (0.52) | MEN1KMT2ANPC1RAB9ASIGMAR1 | |
| SCHEMBL1126310 | 0.78 | SIGMAR1 (0.60) | KMT2ANPC1RAB9ASIGMAR1GAA | |
| SCHEMBL2820867 | 0.74 | HPGD (0.42) | MEN1KMT2ANPC1RAB9AGAA | |
| SCHEMBL2824093 | 0.74 | TRPC6 (0.40) | GAAALDH1A1 | |
| SCHEMBL31035634 | 0.73 | ALDH1A1 (0.51) | MEN1KMT2AL3MBTL1GAAALDH1A1 | |
| SCHEMBL1269266 | 0.73 | ALDH1A1 (0.51) | MEN1KMT2AL3MBTL1GAAALDH1A1 | |
| SCHEMBL2343208 | 0.72 | AKR1C3 (0.49) | MEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL24525802 | 0.72 | GAA (0.40) | GAAALDH1A1KCNH2 | |
| SCHEMBL29813620 | 0.72 | GAA (0.40) | GAAALDH1A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742634-B1 | POLYCYCLIC PYRIMIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN INC (US) | 2010-10-27 | — | — | EP | disclosed |
| EP-1742935-B1 | POLYCYCLIC PYRAZINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN INC (US) | 2010-02-24 | — | — | EP | disclosed |
| US-7642354-B2 | Use treating nervous system disorders, as neuroprotectants, gastrointestinal disorders, cardiovascular disorders; e.g. 2-(5-phenylpyridin-2-ylamino)-6-pyridin-2-ylpyrimidine | ICAGEN, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7560464-B2 | Polycyclic pyrimidines as potassium ion channel modulators | ICAGEN, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20080108600-A1 | Polycyclic Pyridines as Potassium Ion Channel Modulators | ICAGEN, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| EP-1742935-A1 | POLYCYCLIC PYRAZINES AS POTASSIUM ION CHANNEL MODULATORS | Icagen, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1742634-A1 | POLYCYCLIC PYRIMIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAgen, Incorporated (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1740155-A1 | POLYCYLIC THIAZOLES AS POTASSIUM ION CHANNEL MODULATORS | Icagen, Inc. (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1737852-A2 | POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS | Icagen, Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005121126-A1 | POLYCYCLIC PYRAZINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050267089-A1 | Polycyclic pyrimidines as potassium ion channel modulators | ICAGEN, INC. (US) | 2005-12-01 | — | — | US | disclosed |
| WO-2005099673-A1 | POLYCYLIC THIAZOLES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005099711-A1 | POLYCYCLIC PYRIMIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005100349-A2 | POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050239800-A1 | Polycyclic pyrazines as potassium ion channel modulators | ICAGEN, INC. (US) | 2005-10-27 | — | — | US | disclosed |
| US-20050227989-A1 | Polycyclic thiazoles as potassium ion channel modulators | ICAGEN, INC. (US) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267089-A1 | Polycyclic pyrimidines as potassium ion channel modulators | KCNJ2, KCNJ1, KCNJ11 | MEN1 3752/4885KMT2A 908/4885NPC1 1559/4885 |
| US-20080108600-A1 | Polycyclic Pyridines as Potassium Ion Channel Modulators | KCNJ2, KCNH2, KCNQ1 | MEN1 2428/4885KMT2A 563/4885NPC1 1509/4885 |
| US-20050227989-A1 | Polycyclic thiazoles as potassium ion channel modulators | KCNJ2, KCNA3, KCNN3 | MEN1 1698/4885KMT2A 809/4885NPC1 724/4885 |
| US-20050239800-A1 | Polycyclic pyrazines as potassium ion channel modulators | KCNJ2, KCNH2, KCNJ1 | MEN1 2382/4885KMT2A 702/4885NPC1 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.